IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
20.04
+0.48 (2.45%)
At close: May 29, 2025, 4:00 PM
20.05
+0.01 (0.05%)
After-hours: May 29, 2025, 4:27 PM EDT
IDEAYA Biosciences Employees
IDEAYA Biosciences had 131 employees as of December 31, 2024. The number of employees increased by 7 or 5.65% compared to the previous year.
Employees
131
Change (1Y)
7
Growth (1Y)
5.65%
Revenue / Employee
$53,435
Profits / Employee
-$2,344,145
Market Cap
1.76B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
IDYA News
- 15 days ago - Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 - Seeking Alpha
- 23 days ago - IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 23 days ago - IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 6 weeks ago - Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha
- 6 weeks ago - IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PRNewsWire
- 7 weeks ago - IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PRNewsWire